Zhejiang Taimei Calls EGM to Approve New 2026 H Share Award Scheme

An update from Zhejiang Taimei Medical Technology Co Ltd Class H ( (HK:2576) ) is now available.

Zhejiang Taimei Medical Technology Co., Ltd. has convened an extraordinary general meeting for 14 February 2026 in Shanghai to seek shareholder approval for a new 2026 H Share Award Scheme, capped at 10% of the company’s issued H shares (excluding treasury shares) at the date of adoption. The meeting will also vote on sizeable conditional equity award grants to several key executives, including Chairman Zhao Lu and other senior managers, and on authorizing the board to fully implement and manage the scheme, including granting awards, issuing new H shares, adjusting registered capital, amending the Articles, and securing necessary regulatory approvals. The initiative signals an effort to strengthen long-term incentives and align management interests with shareholders, while potentially leading to some dilution as new H shares may be issued under the scheme.

The most recent analyst rating on (HK:2576) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Zhejiang Taimei Medical Technology Co Ltd Class H stock, see the HK:2576 Stock Forecast page.

More about Zhejiang Taimei Medical Technology Co Ltd Class H

Zhejiang Taimei Medical Technology Co., Ltd. is a PRC-incorporated company listed in Hong Kong, operating in the medical technology sector. The company focuses on healthcare-related technology solutions and is governed by a board comprising executive and independent non-executive directors, reflecting a typical listed-company structure aimed at serving both domestic and international investors through its H share listing.

Average Trading Volume: 62,143

Technical Sentiment Signal: Buy

Current Market Cap: HK$2.59B

For detailed information about 2576 stock, go to TipRanks’ Stock Analysis page.